Catalyst Biosciences Interest Expense 2011-2026 | CBIO

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Catalyst Biosciences

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
1.04 M	726 K	-78 K	-91 K	-39 K	1.65 M	-1 K	86 K	1.48 M	23 K	53 K	86 K	132 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.65 M	-91 K	390 K

Quarterly Interest Expense Catalyst Biosciences

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
727 K	-145 K	107 K	-	-75 K	-72 K	122 K	-	-1.33 M	629 K	184 K	-	-1 K	17 K	-17 K	-	-16 K	-25 K	-17 K	-	-7 K	15 K	2 K	-	-	-	-	-	-1 K	30 K	1.47 M	-	85 K	14 K	16 K	-	38 K	16 K	20 K	-	1.44 M	39 K	-	-	5 K	6 K	9 K	-	13 K	14 K	16 K	-	20 K	22 K	26 K	-	39 K	29 K	31 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.47 M	-1.33 M	85.1 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Biogen BIIB	250 M	$ 173.17	0.92 %	$ 25.2 B	USA
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Adagene ADAG	1.11 M	$ 2.4	-3.61 %	$ 135 M	China
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.67	3.38 %	$ 8.83 B	Australia
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
BioXcel Therapeutics BTAI	20.2 M	$ 1.77	-2.75 %	$ 4.49 M	USA
BioLineRx Ltd. BLRX	9.07 M	$ 3.12	0.59 %	$ 908 M	Israel
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Cellectis S.A. CLLS	371 K	$ 4.13	-6.56 %	$ 116 M	France
Ascendis Pharma A/S ASND	65.5 M	$ 233.49	-0.81 %	$ 5 B	Danmark
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Arrowhead Pharmaceuticals ARWR	5.26 M	$ 67.41	0.54 %	$ 9.02 B	USA
Compugen Ltd. CGEN	281 K	$ 2.04	-2.39 %	$ 183 M	Israel
Can-Fite BioPharma Ltd. CANF	227 K	$ 4.36	-2.46 %	$ 9.49 B	Israel
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-20.7 M	-	-	$ 1.01 B	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Adaptimmune Therapeutics plc ADAP	-807 K	-	-15.15 %	$ 60.3 M	Britain
Amphastar Pharmaceuticals AMPH	4.08 M	$ 26.57	2.51 %	$ 1.29 B	USA
Coherus BioSciences CHRS	40.5 M	$ 2.26	9.7 %	$ 213 M	USA
Amneal Pharmaceuticals AMRX	11.8 M	$ 13.59	1.46 %	$ 4.2 B	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Athira Pharma ATHA	3.96 M	-	-	$ 269 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Celldex Therapeutics CLDX	927 K	$ 26.72	3.09 %	$ 1.72 M	USA
Aytu BioScience AYTU	-512 K	$ 2.75	1.85 %	$ 17.3 M	USA
Arena Pharmaceuticals ARNA	4.16 M	-	-6.81 %	$ 3.04 B	USA
Brickell Biotech BBI	5 K	-	-5.38 %	$ 6.06 M	USA